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Abstract 
Objective: To determine the prevalence of nasal septum perforation associated to Histoplasma sp. Material 
and Methods: A retrospective descriptive study was conducted with patients who developed nasal septum 
perforation associated to histoplasmosis. The diagnosis was made based on clinical manifestations and 
confirmed with mycological direct examination with Giemsa stain, culture, serologic tests (immunodiffusion 
method), and histopathology with hematoxylin-eosin, Grocott methenamine (GMS) and Periodic Acid-
Schiff stain (PAS). Results: Out of 1654 medical records reviewed with diagnosis of histoplasmosis in the 
study period, we found 22 cases with nasal septum perforation. Autoimmune disease was present in 6 
patients; all six were on immunosuppressive treatment. Two patients had HIV/AIDS, one of them had also 
paracoccidiodomycoses and the remaining had no apparent underlying disease or conditions. Conclusion: 
Physicians of endemic areas such as Venezuela, must consider this entity in the differential diagnosis with 
other diseases. 
 
Keywords: Mycoses; Histoplasmosis; Immunosuppressive Agents; Acquired Immunodeficiency Syndrome.
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Introduction 
Histoplasmosis is a granulomatous disease with worldwide distribution caused by Histoplasma spp. It 
has been described in every continent except Antarctica; frequently, it has been reported in the United States, 
Mexico, Central and South America. In Venezuela, this mycosis is the main fungal infection causing 
hospitalization and maybe death [1-3]. 
The global burden of histoplasmosis has been increasing, as a result of climate change, progression of 
HIV/AIDS, increasing number of patients with malignancies, organ transplant surgery, immunological 
conditions receiving immunosuppressive treatment, patients at the extremes of age as well as the detriment in 
the population’s socioeconomic conditions (malnutrition among others) [4,5]. 
Usually, infection is limited by cell-mediated immunity. However, neutrophils are unable to destroy 
the fungus and although the macrophages are able to ingest the microorganism, they cannot destroy the fungi 
in tissue. Thus, infected individuals harbor yeasts that remain viable for many years. The dormant organisms 
pose little risk unless the patient becomes immunosuppressed as a result of the aforementioned risk factors 
[4,6]. 
After inhalation of Histoplasma sp microconidia, patients develop a sub-clinical and self-limited disease 
that most often goes unnoticed, and may be indistinguishable from community-acquired viral or bacterial 
pneumonia. The infection usually resolves within 1 to 2 weeks, but in severe cases, disseminated forms can 
occur [7]. 
Muco-cutaneous lesions, while not uncommon, are not prominent in histoplasmosis as they are in 
paracoccidioidomycosis. In chronic disseminated histoplasmosis, ulcers in the tongue, hard palate and nasal 
septum may occur as a consequence of lymphohematic dissemination. Physicians of endemic areas such as 
Venezuela must consider histoplasmosis in the differential diagnosis of any chronic non-healing mucosal lesion 
[8]. 
We have observed upward trends in the number of cases with nasal septum perforation (NSP) due to 
disseminated histoplasmosis. In this matter, we decided to carry out a retrospective analysis of these cases. 
 
Material and Methods 
Study Design 
We conducted a retrospective descriptive study of patients who developed NSP associated to 
histoplasmosis at the Medical Mycology Department “Dr. Dante Borelli”, Tropical Medicine Institute, Central 
University of Venezuela, Caracas, Venezuela. 
 
Data Collection 
Data collected included demographics, epidemiological, clinical and radiological features, diagnostic 
methods, treatment, and follow-up information from each case, as available in a 23-year period (from 1994 to 
2017) from medical records of patients who attended to the Medical Mycology Department “Dr. Dante Borelli” 
referred from different health care centers in all the country. Data were collected on a standardized clinical 
report form. The diagnosis was made based on clinical manifestations and confirmed with mycological direct 
examination with Giemsa stain, culture, serologic tests (immunodiffusion method), and histopathology with 
hematoxylin-eosin, Grocott methenamine (GMS) and Periodic Acid-Schiff stain (PAS). Histopathological 
evaluation of all clinical specimens was performed at the Pathological Anatomy Institute “Dr. José Antonio O’ 
Daly”, Central University of Venezuela. 
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Patients fulfilled at least one of the following criteria: 1) Positive culture for Histoplasma sp. from nasal 
mucosa; 2) Demonstration of Histoplasma sp. by histopathology or cytology; and 3) Positive Histoplasma 
serology by double immunodiffusion with detection of H or M bands. Data regarding treatment, follow-up and 
outcome were included when available. 
 
Data Analysis 
Data were analyzed using IBM SPSS Statistics for Windows Software, version 20 (IBM Corp., 
Armonk, NY, USA). Descriptive statistics were used to calculate the absolute and relative frequencies and 
mean. 
 
Ethical Considerations 
This research was approved by the Independent Committee of Bioethics for Investigation from the 
Bioethics National Center, Protocol No. CIBI-CENABI-05-2020. 
 
Results 
Out of 1654 medical records reviewed with a diagnosis of histoplasmosis, we found 22 cases (1.33%) 
having NSP. Of the 22 cases with NSP, 14 (63.6%) were female and 8 (36.3%) male. The age ranged from 20 to 
98 years; with a mean age of 50.72 years, the most affected were between 20 and 39 years old (8 patients, 
42.1%). Most patients resided in urban areas (68.2%), with most cases coming from the north-central endemic 
region of Venezuela. The rest of the patients came from other endemic areas of the country. 
Eleven (50%) patients had risk factors such as farming/gardening or cave tourism despite their 
occupations. Other risk factors observed were alcoholism (9.1%) and 2 (9.1%) patients were heavy smokers. In 
7 cases (31.8%) the data was missing (Table 1). 
 
Table 1. Distribution of participants according to sociodemographic characteristics. 
Variables N % 
Gender   
Female 14 63.6 
Male 8 36.4 
Residence   
Urban Area 15 68.2 
Rural Area 5 22.7 
Unknown  2 9.1 
Alcoholism   
Yes 2 9.1 
No 22 90.9 
Smoking   
Heavy Smoker 2 9.1 
No 13 59.1 
Missing 7 31.8 
Occupation Known   
Farmer 7 31.8 
Builder 1 4.5 
Housewife 5 22.7 
Others 7 31.8 
Unknow 2 9.1 
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The most relevant clinical sign was septum perforation, observed in all 22 cases (100%) (Figure 1), 
followed by epistaxis (63.6%), crusting  (54.5%), dyspnea  (40.9%), fever (18.1%), cough (18.1%) and muco-
cutaneous manifestations (9%) (nasal mucosa and skin). Other clinical manifestations such as headache, pain, 
rhinorrhea, cacosmia or foul smell, hepatic/splenomegaly, cervical adenomegaly and soft palate perforation was 
present in 6 (27.2%) cases (Table 2). 
 
 
Figure 1. Clinical feature of NSP with fibroscopy. 
 
Table 2. Distribution of participants according to signs and symptoms. 
Signs/Symptoms* N % 
Epistaxis 14 63.6 
Crustings 12 54.5 
Fever 5 22.7 
Dyspnoea 6 27.2 
Cough 3 13.6 
Others 6 27.2 
*Some patients had more than 1 sign/symptom. 
 
Chest radiographs were available in 11 (50%) patients. Seven (31.8%) were reported as having diffuse 
bilateral interstitial pneumonitis. One patient had a tumor mass in the upper right lobe and pulmonary 
infiltrates in middle right lobe. In three patients, chest x-rays were reported as normal. Sinus CT-scan was 
performed in two patients (10.5%) and revealed a perforation in the cartilaginous portion of nasal septum 
(Figure 2). 
Autoimmune disease was present in 6 patients (15.7%), 2 (10.5%) had systemic lupus erythematosus 
(SLE), 2 (10.5%) granulomatosis with polyangiitis, 1 (5.2%) chronic kidney disease (CKD) and, 1 (5.2%) chronic 
inflammatory response by an implant of biopolymers; all six were on immunosuppressive treatment 
(methotrexate, infliximab, and/or corticosteroids). Two patients (10.5%) had HIV/AIDS, one of them (5.2%) 
had also paracoccidiodomycoses (PCM); 1 patient (5.2%) had diabetes mellitus (DM), 1 (5.2%) arterial 
hypertension and the remaining 9 (47.3%) cases had no apparent underlying disease or conditions (Table 3). In 
all cases serology for HIV/AIDS was performed. 
Complete laboratory tests were performed only in four patients. One of them showed pancytopenia, 
high erythrocyte sedimentation rate and abnormal hepatic tests. The remaining three (13.6%) had no 
significant changes in laboratory studies. 
Pulmonary manifestations were registered in six (27.2%) cases whit abnormal chest X-ray. Three 
patients had CT head scans; Figure 2 showed the disruption in posterior portion of nasal septum (condro-
vomerian articulation). 
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Figure 2. Axial cut of nose and paranasal sinus showing disruption in posterior portion of nasal septum 
(condro-vomerian articulation). 
 
Table 3. Distribution of participants, according to comorbidities. 
Comorbidities N % 
HIV/AIDS 2 9.1 
Lupus Erythematosus 3 13.6 
Wegener Granulomatosis 2 9.1 
Paracoccidioidomycoses 2 9.1 
Arterial Hypertension 2 9.1 
Diabetes 2 9.1 
Chronic Renal Failure 1 4.5 
None 9 40.9 
 
In all cases, the diagnosis was achieved by direct examination of the samples with Giemsa stain and 
histopathological tissue exam. All the samples showed findings of inflammatory process; granulomatous 
response was observed in 18 (81.8%) cases, and necrosis foci in 12 (54.5%). The GMS and PAS stain revealed in 
all cases, small intracellular and extracellular yeast forms compatible with Histoplasma sp. (Figure 3). Culture 
and serology were performed in 8 patients, with 4 (21%) resulting in a positive culture and one case (4.5%) 
with a conclusive serology. For the remaining cases, data was missing. 
Antifungal therapy was adequately registered for 14 (63.6%) patients who received Itraconazole with 
an average duration of 12 months; 8 patients improved, 3 died and the other 3 were lost to follow-up. In one 
case (4.5%), the infection was fulminant despite treatment with amphotericin B. This patient died due to delay 
in treatment by a misdiagnosis of tuberculosis. Multi-organic failure and respiratory distress were the cause of 
death in 4 (18.1%) patients, including the aforementioned. One patient had HIV/AIDS and was lost to follow-
up. Data about treatment was not available in 7 (31.8%) cases. The seven (31.8%) remaining patients were lost 
to follow- up (Table 4). Some patients were referred for surgical repair. 
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Figure 3. A and B: NSP border showed chronic inflammatory infiltrates (H&E, X400 and X1000). C: 
Non-necrotizing granulomatous response giant cell with intracitoplasmatic yeast forms suggesting of 
Histoplasma sp. (yellow arrow, H&E x1000). D: Multiple yeast forms suggesting of Histoplasma sp. 
(Gomori-Grocott x400). E: Multiple intracellular blastoconidias morphologically suggestive of 
Histoplasma sp. (PAS x400). F: Intracellular and extracellular blastoconidia morphologically 
suggestive of Histoplasma sp. (Diff-Quik® x1000). 
 
Discussion 
Histoplasmosis is the most common systemic mycosis worldwide [1,2,4]. It has a wide spectrum of 
clinical manifestations that mostly depends on the host immunological status and the fungal inoculum size 
[2,8-10]. After inhalation, conidia transform into yeast forms in the lungs, which are phagocyted by tissue-
resident macrophages. In the majority of cases, the yeasts are eliminated by the macrophages and the infection 
is either asymptomatic or mild and self-limiting. However, Histoplasma sp. limits its detection by pattern 
recognition receptors (PRR). The C-type lectin receptor dectine-1 is a major receptor for recognition of the β-
glucans of the fungal cell wall. Most strains of Histoplasma sp. produce a layer of α-linked glucans that overlies 
the β-glucans reducing its detection in the lung tissue. In patients whit faulty T-cell mediated immunity, the 
localized containment of the fungi does not occur and systemic dissemination via reticuloendothelial or 
hematogenous pathway take place. Approximately 10% of histoplasmosis cases develop progressive 
disseminated forms that can affect any organ, including muco-cutaneous lesions [2,8]. 
NSP is an uncommon clinical presentation of Histoplasma sp infection [11,12]. It may mimic other 
pathologies including trauma, autoimmune or immunosuppressing disorders (SEL, Rheumatoid Arthritis, etc.), 
infections (Syphilis, leishmaniasis, tuberculosis, leprosy and other fungal infections), neoplasia and other causes 
such as steroid or vasoconstrictor nasal spray usage, chronic cocaine abuse and chrome industry mining [13-
18].  
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Table 4. Distribution of participants according to clinical and epidemiological characteristics. 
No Sex Age (Years) Risk Factors 
Clinical 
Presentation 
Lesions Diagnosis Treatment Comorbidity Chest X Ray Follow up 
1 F 27 Contact with landslide Epistaxis, nose 
wound with crusts 
NSP Biopsy, culture 
and direct 
examination 
Itraconazole 
V.O 400 mgs 
1 year 
None Interstitial 
pneumonitis 
Improvement 
2 F 20 Farming Epistaxis, nose 
wound with crusts, 
cough, dyspnea, 
weight loss, 
cutaneous lesions 
NSP Direct 
examination 
Itraconazole 
V.O 400 mgs 
1 year 
HIV/AIDS and 
PCM 
Interstitial 
pneumonitis 
Dead 
3 F 27 Barnyard fowl contact Epistaxis, cough, 
dyspnea 
NSP Biopsy, culture Itraconazole 
V.O 400 mgs 
1 year 
None Interstitial 
pneumonitis 
Dead 
4 M 38 Cave tourism Epistaxis, productive 
cough, dyspnea 
NSP Biopsy and 
direct 
examination 
Itraconazole 
V.O 400 mgs 
1 year 
None Interstitial 
pneumonitis 
Improvement 
5 M 73 Builder, treatment with 
oral steroids and 
methotrexate 
Epistaxis, nose 
wound with crusts, 
fever, dyspnea, nasal 
discharge, cephalea 
NSP Culture and 
direct 
examination 
Itraconazole 
V.O 400 mgs 
1 year 
Granulomatosis 
with 
polyangiitis 
Interstitial 
pneumonitis 
Improvement 
6 M 47 Farming, alcoholism, 
barnyard fowl contact 
Nose wounds with 
crusts, fever, adeno 
and splenomegaly, 
cough, dyspnea 
NSP Culture and 
direct 
examination 
Itraconazole 
V.O 400 mgs 
1 year 
None Tumor mass 
upper right lobe 
and pulmonary 
infiltrates 
Improvement 
7 M 98 Unknown Epistaxis NSP Biopsy Unknown None Unknown Unknown 
8 F 33 Treatment with anti-
TNFα 
Epistaxis NSP Biopsy Unknown SEL Unknown Unknown 
9 F 75 Unknown Nose wounds with 
crusts 
NSP Biopsy Unknown DM II Unknown Dead 
10 F 48 Unknown Cacosmia, nose 
wound with crusts 
NSP Biopsy Itraconazole 
V.O 400 mgs 
1 year 
SEL Unknown Unknown 
11 F 75 Treatment with steroids Epistaxis NSP Biopsy Unknown Granulomatosis 
with 
polyangiitis 
Unknown Unknown 
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12 F 29 Unknown Nose wounds with 
crusts 
NSP Biopsy Unknown HIV/AIDS Unknown Unknown 
13 M 56 Unknown Epistaxis and pain NSP Biopsy Unknown Unknown Unknown Unknown 
14 F 78 Treatment with steroids Pain NSP Biopsy Unknown CKD Unknown Unknown 
15 F 39 Treatment with 
Etanercept© (TNFα 
blocker) 
Epistaxis NSP Biopsy Itraconazole 
V.O 400 mgs 
1 year 
None Normal Improvement 
16 M 49 Contact with soil dust Epistaxis, nose 
wound with crusts 
NSP Biopsy Itraconazole 
V.O 400 mgs 
1 year 
None Normal Improvement 
17 M 51 Poultry man Epistaxis, nasal 
obstruction 
NSP Direct 
examination 
Itraconazole 
V.O 400 mgs 
1 year 
None Normal Improvement 
18 F 70 Cave tourism, farming Epistaxis, nose 
wounds with crusts, 
dyspnea 
NSP Serology, 
culture and 
biopsy 
Itraconazole 
V.O 400 mgs 
1 year 
AHT Interstitial 
pneumonitis 
Improvement 
19 F 20 Farming Cacosmia, nose 
wounds with crusts, 
dyspnea, weight loss, 
fever, hepato-
splenomegaly 
NSP and 
palate 
perforation 
Biopsy Amphotericin 
B 
None Interstitial 
pneumonitis 
Dead 
20 F 47 Treatment with Treatment 
with anti-TNFα, heavy 
smoker, barnyard fowl 
contact 
Epistaxis, fever NSP Biopsy Itraconazole 
V.O 400 mgs 
1 year 
LES Unknown Unknown 
21 F 70 Cave tourism Wight loss, dyspnea, 
crusting, rhinitis 
NSP Biopsy Itraconazole 
V.O 400 mgs 
1 year 
PCM Interstitial 
pneumonitis 
Unknown 
22 M 46 Contact with soil dust, 
smoker and alcoholism 
Wight loss, dyspnea, 
crusting, hepato-
splenomegaly cervical 
adenomegaly 
NSP Biopsy Itraconazole 
V.O 400 mgs 
1 year 
DM II and 
AHT 
Unknown Unknown 
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Why NSP occurs in histoplasmosis is unknown. The mechanisms related with this manifestation are 
complex and depend on the individual immune response. Host immune response toward fungal pathogens is 
initiated by the recognition of invading fungi via PRR expressed on antigen presenting cells. Receptor-
mediated signaling induces downstream events such as cytokine and chemokine release, phagocytosis, and 
respiratory oxygen species (ROS) burst, ultimately leading to killing the fungus. In addition, the cytokine 
responses shape the induction of Th1 and Th17 adaptive immune response. IL 12 drives IFN-gamma 
production by T-helper 1 (Th1) cells, crucial for phagocytosis activation or avoid of immunological response 
[6,19-22]. 
Macrophages of the innate branch of the immune system not only are ineffective in killing yeasts of 
Histoplasma sp. but also can behave as the principal host cell and vehicle for its dissemination. Once cell-
mediated immunity is triggered, Th1-cytokine signals (e.g., tumor necrosis factor alpha [TNF-] and gamma 
interferon [IFN-]) activate phagocytic cells and potentiate their antifungal mechanisms [4,6,23]. 
In this study, we found patients that were farmers and housewives with a history of 
farming/gardening or cave tourism, builders exposed to roost droppings, also patients who frequently traveled 
around the country and were exposed to climatic changes and elderly patients (70-98 years old) among others. 
These conditions have been commonly implicated as risk factors for histoplasmosis [2,4,8,9]. 
Histoplasmosis is acquired through the respiratory route. The acquisition is related to human 
activities and climatic conditions that increase the risk of exposure to these organisms in susceptible 
individuals. Factors such as intense urbanization and climatic changes may cause the fungi's ecological 
impairment, leading to dispersion of the conidia, which could be inhaled by exposed individuals. Additionally, 
there are other sources for exposure to Histoplasma sp., including lumberjacking, street-swipping, and 
dovecotes cleansing, such as attics as suggested elsewhere. Considering the occupation of patients at the 
moment of the diagnosis may give an important epidemiological clue of risk factors [1,2,4,5,8,9]. 
The clinical manifestations we found were mainly NSP, along with epistaxis in 63.6% cases, crusting 
(54.5%), dyspnea (27.2%), fever (22.7%), cough (13.6%), and 9% had muco-cutaneous manifestations (nasal 
mucosa and skin). Other symptoms reported included nasal obstruction, rhinorrhea, chronic rhinosinusitis and 
pain. One of our patients had soft palate perforation. Pulmonary manifestations were registered in six cases 
whit abnormal chest X-ray. These findings are similar to what is described in the literature [12,24-30]. 
As aforementioned, NSP clinical manifestations could be variable being sometimes an occasional 
finding in the rhinoscopy [31]. It has multiple causes being its physiopathological basis a mucosal and 
perichondrium lesion with local blockage of the blood supply. Blood irrigation of the nasal septum arises from 
maxillary artery branches, which converge to the muco-perichondrial leaflets that covers each side of the septal 
cartilage. Any threat to the vascularity of these leaflets can jeopardize the underlying cartilage, predisposing to 
septal perforation. This condition disturbs the nasal airflow, and creates turbulence, which causes mucosal 
dryness that predisposes scabbing and epistaxis. Unfortunately, deformity of the nasal dorsum is noticed when 
large perforation occurs and can threaten dorsal nasal support. The local inflammation may cause granulation 
tissue or excessive crusting. An intraoral exam can rule out palatal involvement [11]. Thus, cases with 
perforation of the nasal septum and scabbing ulcers should suggest the possibility of histoplasmosis. 
In our study, we found six patients who were receiving immunosuppressive drugs as methotrexate, 
infliximab, corticosteroids, to treat various clinical conditions such as SEL, granulomatosis with polyangiitis, 
chronic renal failure, and chronic inflammatory response by biopolymer implants. This observation is 
consistent with other authors who described 7 cases of disseminated histoplasmosis in patients with 
autoimmune disorders receiving immunosuppressant agents, two of them with NSP [24]. Another multicenter 
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study with 98 patients with histoplasmosis was considered, all with concomitant autoimmune disorders and 
tumor necrosis factor alpha blocker (TNF-α) therapy, but none of them had NSP [32]. 
Although TNF-α blocker therapy has revolutionized the treatment of several autoimmune disorders, 
the use of immunosuppressive medications such as TNF-α blockers has resulted in a rising trend of 
histoplasmosis, since this cytokine plays a critical role in the host’s immune response to Histoplasma sp 
[30,32,33]. Ideally, healthcare providers should be able to suspect and diagnose histoplasmosis in an endemic 
area such as Venezuela, in any condition being treated with this kind of therapy.  
Although histoplasmosis is usually seen in immunocompromised patients, in 9 of our cases, there was 
no evidence of immunosuppression. Primary immunodeficiencies (PID) in Venezuela are rarely diagnosed, and 
recognition of those who may have underlying PID could be a challenge [2]. Also, individuals who are 
apparently healthy may develop histoplasmosis, but it is important to bear in mind that malnutrition and stress 
due to the political situation in our country could have an influence in the immune response of the host. Also, 
in Venezuela, currently, health centers lack diagnostic tools, possibly leading to misdiagnosis in many patients, 
with the consequence of an upraise in the morbidity and mortality of the disease. Defects of T-cell development 
and differentiation, phagocytic functions and pathways involved in innate recognition and downstream 
signaling, have been associated with increasing cases of histoplasmosis [4]. Therefore, individuals who are 
apparently healthy could also develop histoplasmosis. Two of our cases had HIV/AIDS, both were females, of 
20 and 29 years old, respectively. The first of them also had PCM with respiratory manifestations and 
abnormal findings in the chest radiograph and died. The other case was lost to follow up. 
Human immunodeficiency virus infection is the most common cause of dissemination or 
extrapulmonary forms of histoplasmosis. It is considered an (AIDS) - defining illness in the world [4,34,35]. In 
Venezuela, histoplasmosis occurs in up to 39% of HIV infected patients and represents the first manifestation of 
AIDS in up to 50-70% of patients, causing a high rate of morbidity. Due to the lack of diagnostic facilities and 
algorithms, histoplasmosis is underdiagnosed in many HIV patients and it is considered an “invisible burden” 
of AIDS in our country [35]. 
Almost all studies in the international literature, report NSP in patients with HIV/AIDS. A recent 
case report and literature review showed a Haitian female with HIV/AIDS and nasal septum destruction along 
with another 18 cases, almost all have HIV/AIDS [25]. The same data has been reported elsewhere 
[26,28,29]. 
Due to the small size of the fungus (2-4 µm), the histoplasmosis diagnosis is usually done by isolation 
in culture. This process can take a long time and may delay the diagnosis and treatment [12]. Although 
culture is the gold standard diagnostic test, it takes up to four weeks to provide conclusive results. Thus, in 
severe cases, when prompt intervention is required, it may not be effective. Additionally, a fungal culture is 
positive in only approximately 25% to 40% of the cases. In severe chronic lesions, GMS staining allows 
visualization of the infectious agent and aids in diagnosis. Therefore, the histopathological exam is a very 
important tool. In our cases, the thorough search and review by well-trained personnel, allowed us to 
successfully found the small intracellular yeast of Histoplasma sp. in all samples reviewed. In some of the cases, 
it was the first positive result given to the patient, which allowed appropriate treatment in a short time 
[2,8,34]. 
This study had some limitations. Being a retrospective and descriptive analysis, we lacked specific data 
that were not collected for each patient. Since we managed not all patients, procedures of data collection, 
sample taking, treatment, and follow up of the patients were not uniform. Although missing data may partly 
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compromise the study’s conclusions, the importance of clinical manifestations, diagnosis, treatment, and 
outcome of the patients is not overruled. 
 
Conclusion 
Suspicion and diagnosis of Histoplasma sp. in patients who present with nasal-perforation and risk 
factors for the disease, is of utmost importance. Such knowledge will allow us to better understand its 
epidemiology, clinical patterns and response to treatment. 
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